Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech Inc. (NYSE American:AIM) announced a promising breakthrough in combating SARS-CoV-2, demonstrating that Ampligen, a dsRNA TLR3 agonist, reduced infectious viral yields by 90% in an in vitro model. This result supports the potential of Ampligen as an intranasal prophylactic treatment for COVID-19. CEO Thomas K. Equels expressed optimism about these findings, highlighting the need for further human testing. The company aims to advance clinical trials based on these results, although it notes the requirement for substantial additional research to confirm effectiveness in human subjects.
AIM ImmunoTech (NYSE American:AIM) announced its participation in The LD 500 Investor conference, taking place virtually from September 1-4, 2020. CEO Thomas K. Equels is scheduled to present on September 1st at 1:20 p.m. Eastern Time. The presentation will be live-streamed on the event's platform. One-on-one meetings with AIM are available through video calls. The LD 500 features prominent small and micro-cap companies, along with keynotes from industry leaders. Interested parties can register via provided links or contact details.
AIM ImmunoTech (NYSE American: AIM) reported a significant increase in cash, reaching $40.3 million as of June 30, 2020, compared to $8.8 million at year-end 2019. The company's R&D expenses rose to $1.46 million from $1.10 million year-over-year. AIM is progressing with a Phase 1/2a trial of Ampligen combined with interferon alfa-2b for cancer patients with COVID-19, supported by agreements with key institutions. The company also aims to address post-COVID-19 chronic fatigue-like illnesses. AIM is pursuing approvals and launches for Ampligen in multiple markets.
AIM ImmunoTech (NYSE American:AIM) announced significant updates in its second-quarter 2020 report. The company's cash reserves increased to $40.3 million from $8.8 million at the end of 2019. Research and development expenses rose to $1.46 million, while general and administrative costs decreased to $1.72 million. AIM is engaged in various clinical trials, including a Phase 1/2a trial of Ampligen for cancer patients with COVID-19, and is collaborating with multiple institutions for further research into Ampligen's potential as a treatment and vaccine adjuvant.